Linked Life Data

11334721

Source:http://linkedlifedata.com/resource/pubmed/id/11334721

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2001-5-3
pubmed:abstractText
Treatment options in patients with recurrent non-small-cell lung cancer (NSCLC) remain limited as a result of the poor activity of older agents after platinum-based therapy. The present phase II study aimed to evaluate the combination of gemcitabine and vinorelbine in patients with relapsed NSCLC after pretreatment with taxane+platinum-based regimens, since gemcitabine has demonstrated activity in that setting and the combination has been well tolerated in previous phase I/II studies. Patients with advanced NSCLC (stages III/IV), World Health Organization (WHO), Performance Status (PS) < or = 2, prior platinum+taxane-based chemotherapy and unimpaired haematopoietic and organ function were eligible. Chemotherapy was administered as follows: vinorelbine 25 mg/m(2) followed by gemcitabine 1000 mg/m(2), both administered on days 1 and 8, recycled every 3 weeks. 40 patients were entered and 39 were evaluable for response and all 40 for toxicity: median age was 61 years (range 50-72 years), median PS=1 (range 0-2), gender ratio=37 males/3 females, stages at initial diagnoses were IIIA=2, IIIB=14, IV=24. Metastatic sites included: lymph nodes: 23, bone: 4, liver: 5, brain: 4, lung nodules: 9, adrenals: 8, pleural effusion: 4. 22 patients had prior paclitaxel/ifosfamide/cisplatin treatment. Objective responses were; partial response (PR): 9/40 (22.5%), stable disease (SD): 13/40 (32.5%) and progressive disease (PD) 18/40 (45%). The median time-to-progression (TTP) was 4.5 months (range 1-17 months) and median survival 7 months (range 2-17+ months). 1-year survival was 17%. Grade 3 neutropenia was seen in 33% of patients. There was no grade 4 neutropenia and no episodes of febrile neutropenia. No grade 3/4 thrombocytopenia or grade 3/4 other non-haematological toxicities were observed. The combination of gemcitabine/vinorelbine is active and well tolerated in patients with advanced NSCLC failing prior taxane/platinum therapy. This regimen represents a tolerable and effective combination to apply in the palliative treatment of relapsed NSCLC.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0959-8049
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
972-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11334721-Adult, pubmed-meshheading:11334721-Aged, pubmed-meshheading:11334721-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11334721-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:11334721-Cisplatin, pubmed-meshheading:11334721-Deoxycytidine, pubmed-meshheading:11334721-Female, pubmed-meshheading:11334721-Humans, pubmed-meshheading:11334721-Ifosfamide, pubmed-meshheading:11334721-Infusions, Intravenous, pubmed-meshheading:11334721-Lung Neoplasms, pubmed-meshheading:11334721-Male, pubmed-meshheading:11334721-Middle Aged, pubmed-meshheading:11334721-Neoplasm Recurrence, Local, pubmed-meshheading:11334721-Paclitaxel, pubmed-meshheading:11334721-Patient Compliance, pubmed-meshheading:11334721-Survival Analysis, pubmed-meshheading:11334721-Treatment Outcome, pubmed-meshheading:11334721-Vinblastine
pubmed:year
2001
pubmed:articleTitle
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
pubmed:affiliation
Department of Medicine, Medical Oncology Unit, Helena-Venizelou Hospital, 21 Apolloniou Street, GR-163 41, Athens, Greece. ckosm@ath.forthnet.gr
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II